Showing results (1-10 of 48) with videos related to
Sort By:
Pageof 5
Current Opinion in Investigational Drugs (London, England : 2000)|January 8, 2009
Pharmacotherapy in post-traumatic stress disorder: evidence from randomized controlled trialsGregory M Sullivan, Yuval NeriaThe Psychiatric Clinics of North America|July 26, 2002
Finding a home for post-traumatic stress disorder in biological psychiatry. Is it a disorder of anxiety, mood, stress, or memory?Gregory M Sullivan, Jack M GormanCurrent Psychiatry Reports|April 27, 2013
Neural, psychophysiological, and behavioral markers of fear processing in PTSD: a review of the literatureErel Shvil, Heather L Rusch, Gregory M Sullivan, et al.Journal of Clinical Immunology|April 29, 2026
First-in-Human, Phase 1, Randomized, Double-Blind, Placebo-Controlled Study of TNX-1500, an Fc-Modified anti-CD154 Monoclonal Antibody, Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single-Ascending Doses in Healthy AdultsSeth Lederman, Bruce L Daugherty, Nancy Herje, et al.Biological Psychiatry|May 14, 2003
Rodent doxapram model of panic: behavioral effects and c-Fos immunoreactivity in the amygdalaGregory M Sullivan, John Apergis, Jack M Gorman, et al.Arthritis Care & Research|May 11, 2023
Efficacy and Safety of Sublingual Cyclobenzaprine for the Treatment of Fibromyalgia: Results From a Randomized, Double-Blind, Placebo-Controlled TrialSeth Lederman, Lesley M Arnold, Ben Vaughn, et al.Biological Psychology|December 3, 2014
Toward a translational approach to targeting the endocannabinoid system in posttraumatic stress disorder: a critical review of preclinical researchSantiago Papini, Gregory M Sullivan, Denise A Hien, et al.Clinical Pharmacology in Drug Development|April 8, 2026
Steady-State Pharmacokinetic Properties of TNX-102 SL, a Sublingual Tablet Formulation of Cyclobenzaprine Hydrochloride (HCl), With Daily Dosing in Healthy Volunteers: A Randomized, Open-Label TrialGregory M Sullivan, Bernd Meibohm, Errol Gould, et al.The International Journal of Neuropsychopharmacology|November 2, 2005
Elevated cerebrospinal fluid 5-hydroxyindoleacetic acid levels in women with comorbid depression and panic disorderGregory M Sullivan, Maria A Oquendo, Yung-yu Huang, et al.Clinical Pharmacology in Drug Development|February 27, 2026
Single-Dose Pharmacokinetic Assessment of TNX-102 SL (Cyclobenzaprine HCl Sublingual Tablets): Results From Randomized, Open-Label Studies in Healthy VolunteersBruce L Daugherty, Bernd Meibohm, Gregory M Sullivan, et al.Pageof 5